Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
Summit Therapeutics opened clinical trial sites for SMT112-216, a randomized multiregional Phase II study of ivonescimab-based regimens in previously untreated advanced clear cell renal cell carcinoma. The ~100-patient study, run with partner Akeso at sites in the U.S. and China, tests ivonescimab alone and combined with cadonilimab or ipilimumab against a nivolumab-plus-ipilimumab standard-of-care comparator.
Key figures
- Drug Name
- ivonescimab (SMT112/AK112)
- Phase Of Trial
- Phase II
- Study id
- SMT112-216
- Nct number
- NCT07877194
- Pdufa date
- November 14, 2026
- Planned enrollment
- 100
- Phase3 studies ivonescimab
- 16
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.